The promyelocytic leukemia (PML) tumor suppressor of acute promyelocytic leukemia (APL)
is essential for a number of proapoptotic and growth-suppressive pathways as well as for the …

The promyelocytic leukemia (PML) tumor suppressor of acute promyelocytic leukemia (APL)
regulates major apoptotic and growth-suppressive pathways. In APL, PML is involved in a …

Acute promyelocytic leukaemia (APL) is characterized by the PML/RARA fusion transcript.
PML and RARA mutations have been shown to directly respond to arsenic trioxide (ATO) …

The promyelocytic leukemia (PML) gene encodes a putative tumor suppressor gene
involved in the control of apoptosis, which is fused to the retinoic acid receptor α (RARα) …

Acute promyelocytic leukemia (APL) is a distinct subtype of myeloid leukemia that in the
USA and Italy alone affects more than 3,000 individuals every year. APL is characterized by …

The promyelocytic leukaemia gene (Pml) is a tumor suppressor identified in acute
promyelocytic leukaemia (APL), where it is fused to RARα gene as a result of the …

The role of the promyelocytic leukemia (PML) protein has been widely tested in many
different contexts, as attested by the hundreds of papers present in the literature. In most of …

RARA (retinoic acid receptor alpha) haploinsufficiency is an invariable consequence of t (15;
17)(q22; q21) translocations in acute promyelocytic leukemia (APL). Retinoids and RARA …

Translocation t (15; 17)(q22; q21) is an acquired clonal cytogenetic change present in
almost all cases of acute promelocytic leukemia (APL). The molecular genetic basis of the …

The nonrandom chromosomal translocation t (15; 17)(q22; q21) in acute promyelocytic
leukemia (APL) juxtaposes the genes for retinoic acid receptor α (RARα) and the putative …